$AQU
Aquaron Acquisition Corp. Stock $aqu

$aqu Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024039767 Filed on May 03, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$89.88K	$109.0K	$861.8K
YoY Change	-74.32%	-48.1%	291.74%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$89.88K	$109.0K	$861.8K
YoY Change	-74.32%	-48.1%	291.74%
Operating Profit	-$89.88K		-$861.8K
YoY Change	-74.53%		289.91%
Interest Expense	$417.8K	$418.6K	$2.122M
YoY Change	-29.18%	-4.86%	382.27%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	$327.9K	$309.6K	$1.260M
YoY Change	36.64%	40.74%	472.8%
Income Tax	$84.44K	$27.88K	$262.2K
% Of Pretax Income	25.75%	9.0%	20.81%
Net Earnings	$98.81K	$281.8K	$997.9K
YoY Change	-34.91%	65.74%	508.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.02	$0.03	$0.17
COMMON SHARES
Basic Shares Outstanding	4.553M shares	4.553M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.70K	$340.00	$340.00
YoY Change	-99.95%	-100.0%	-100.0%
Cash & Equivalents			$340.00
Short-Term Investments
Other Short-Term Assets	$0.00	$2.190K	$2.190K
YoY Change	-100.0%	-99.0%	-99.0%
Inventory
Prepaid Expenses		$2.188K
Receivables
Other Receivables
Total Short-Term Assets	$27.70K	$2.527K	$2.530K
YoY Change	-99.95%	-100.0%	-100.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$32.49M	$31.96M	$31.96M
YoY Change
Other Assets	$0.00	$144.7K	$144.7K
YoY Change
Total Long-Term Assets	$32.49M	$32.10M	$32.10M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$27.70K	$2.527K	$2.530K
Total Long-Term Assets	$32.49M	$32.10M	$32.10M
Total Assets	$32.52M	$32.11M	$32.11M
YoY Change	-42.19%	-42.36%	-42.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$85.77K	$149.1K	$149.1K
YoY Change	-61.01%	6.46%	6.46%
Accrued Expenses	$29.29K	$18.50K	$18.50K
YoY Change	192.9%	85.0%	85.0%
Deferred Revenue
YoY Change
Short-Term Debt	$1.419M	$1.040M	$1.040M
YoY Change	491.1%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.231M	$1.917M	$1.917M
YoY Change	-31.02%	-32.29%	-32.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.526M	$2.526M	$2.526M
YoY Change
Total Long-Term Liabilities	$2.526M	$2.526M	$2.526M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.231M	$1.917M	$1.917M
Total Long-Term Liabilities	$2.526M	$2.526M	$2.526M
Total Liabilities	$4.756M	$4.443M	$4.443M
YoY Change	47.1%	56.94%	56.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.729M	-$4.296M
YoY Change	-1618.23%	-2790.22%
Common Stock	$163.00	$163.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.729M	-$4.295M	$27.66M
YoY Change
Total Liabilities & Shareholders Equity	$32.52M	$32.11M	$32.11M
YoY Change	-42.19%	-42.36%	-42.36%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$98.81K	$281.8K	$997.9K
YoY Change	-34.91%	65.74%	508.23%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$140.2K	-$103.2K	-$653.2K
YoY Change	-48.68%	-63.15%	125.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$114.4K	-$277.0K	$25.58M
YoY Change	-1244.2%	-99.5%	-146.53%
Cash From Investing Activities	-$114.4K	-$277.0K	$25.58M
YoY Change	-974.38%	-99.5%	-146.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$281.9K	373.3K	-$24.99M
YoY Change	17.48%	-99.33%	-145.17%
NET CHANGE
Cash From Operating Activities	-$140.2K	-103.2K	-$653.2K
Cash From Investing Activities	-$114.4K	-277.0K	$25.58M
Cash From Financing Activities	$281.9K	373.3K	-$24.99M
Net Change In Cash	$27.36K	-6.940K	-$56.95K
YoY Change	-236.54%	-113.88%	-240.87%
FREE CASH FLOW
Cash From Operating Activities	-$140.2K	-$103.2K	-$653.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41470
CY2023	dei	Entity Registrant Name EntityRegistrantName	AQUARON ACQUISITION CORP.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2760193
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	515 Madison Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	8th Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
CY2023	dei	City Area Code CityAreaCode	(646)
CY2023	dei	Local Phone Number LocalPhoneNumber	970 2181
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	30560838.7	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4553150	shares
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	1195
CY2023	dei	Auditor Name AuditorName	UHY LLP
CY2023	dei	Auditor Location AuditorLocation	New York
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	339	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	57284	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2188	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	222346	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2527	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	279630	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	144680	usd
CY2022Q4	us-gaap	Assets Assets	55700859	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	149045	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	140075	usd
CY2023Q4	aqu	Franchise Tax Payable FranchiseTaxPayable	18495	usd
CY2022Q4	aqu	Franchise Tax Payable FranchiseTaxPayable	13086	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	353013	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	51753	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	31960267	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	55421229	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	32104947	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	55421229	usd
CY2023Q4	us-gaap	Assets Assets	32107474	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	259438	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1916669	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	304760	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	2525896	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	2525896	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4442565	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2830656	usd
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2930090	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2930090	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5417180	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5417180	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	31960268	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	47571463	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1623060	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1623060	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1623060	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1623060	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	163	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	163	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5138905	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4295522	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	159672	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4295359	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5298740	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32107474	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55700859	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	832906	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	207495	usd
CY2023	us-gaap	Franchisor Costs FranchisorCosts	28923	usd
CY2022	us-gaap	Franchisor Costs FranchisorCosts	13536	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-861829	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-221031	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1980430	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	259976	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	141556	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	176876	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1260157	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	215821	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	262240	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	51753	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	997917	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	164068	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5298740	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	10332578	usd
CY2023	aqu	Excise Tax Liability ExciseTaxLiability	-259438	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	997917	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4295359	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20604	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	54171800	usd
CY2022	aqu	Stock Issued During Period Value Sale Of Private Placement Units StockIssuedDuringPeriodValueSaleOfPrivatePlacementUnits	2687654	usd
CY2022	aqu	Stock Issued During Period Value Underwriter Commissions StockIssuedDuringPeriodValueUnderwriterCommissions	-2708590	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1465333	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	44011103	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3560360	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	164068	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5298740	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	997917	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	164068	usd
CY2023	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	1980430	usd
CY2022	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	259976	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	141556	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	176876	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	144680	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-220158	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	222346	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8970	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	140075	usd
CY2023	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	5409	usd
CY2022	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	13086	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	381040	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	51753	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-653172	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-290216	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	54984377	usd
CY2023	aqu	Cash Withdrawn From Trust Account To Public Stockholder Redemption CashWithdrawnFromTrustAccountToPublicStockholderRedemption	25943773	usd
CY2023	aqu	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	490000	usd
CY2023	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund	129175	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25582948	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-54984377	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	54171800	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2687654	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	100	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	370000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000	usd
CY2023	aqu	Payment To Related Party PaymentToRelatedParty	-97052	usd
CY2022	aqu	Payment To Related Party PaymentToRelatedParty	-99546	usd
CY2023	aqu	Proceeds From Promissory Note Bestpath ProceedsFromPromissoryNoteBestpath	490000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	25943773	usd
CY2022	aqu	Payment Of Underwriters Commissions PaymentOfUnderwritersCommissions	812577	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	631506	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	300000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24986721	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55315017	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-56945	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	40424	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57284	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16860	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	339	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57284	usd
CY2022	aqu	Initial Classification Of Common Stock Subject To Redemption InitialClassificationOfCommonStockSubjectToRedemption	44011103	usd
CY2022	aqu	Allocation Of Offering Costs To Common Stock Subject To Redemption AllocationOfOfferingCostsToCommonStockSubjectToRedemption	3714253	usd
CY2022	aqu	Deferred Offering Costs In Accrued Offering Expenses DeferredOfferingCostsInAccruedOfferingExpenses	2525896	usd
CY2023	aqu	Accretion Of Common Stock To Redemption Valuetwo AccretionOfCommonStockToRedemptionValuetwo	10332579	usd
CY2022	aqu	Accretion Of Common Stock To Redemption Valuetwo AccretionOfCommonStockToRedemptionValuetwo	3560360	usd
CY2023	aqu	Exercise Tax Payable Charged Against Retained Earnings ExerciseTaxPayableChargedAgainstRetainedEarnings	259438	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	105660	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	79780	usd
CY2023	aqu	Other Payable Due To Related Party OtherPayableDueToRelatedParty	99846	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 — Description of Organization and Business Operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aquaron Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated as a Delaware corporation on March 11, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although the Company is not limited to a particular industry or sector for purposes of consummating a Business Combination, the Company intends to focus on operating business in the new energy sector. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company had not commenced any operations. All activities through December 31, 2023 are related to the Company’s formation and the initial public offering (“IPO” as defined below), and subsequent to the IPO, identifying a target company for an initial business combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s sponsor is Aquaron Investments LLC (the “Sponsor”), a Delaware limited liability company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration statement for the Company’s IPO became effective on October 3, 2022. On October 6, 2022, the Company consummated the IPO of 5,000,000 units at an offering price of $10.00 per unit (the “Public Units’), generating gross proceeds of $50,000,000. Simultaneously with the IPO, the Company sold to its Sponsor 256,250 units at $10.00 per unit (the “Private Units”) in a private placement generating total gross proceeds of $2,562,500, which is described in Note 4.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company granted the underwriter a 45-day option to purchase up to an additional 750,000 units at the IPO price to cover over-allotments, if any. On October 14, 2022, the underwriters partially exercised the over-allotment option to purchase 417,180 Units (“Over-Allotment Option Units”) at $10.00 per Unit generating total gross proceeds of $4,171,800. On October 14, 2022, simultaneously with the sale of the Over-Allotment Option Units, the Company consummated the Private Placement of an additional 12,515.40 Private Units generating gross proceeds of $125,154.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A total of $54,984,377 of the net proceeds from the sale of the Units in the IPO (including the Over-Allotment Option Units) and the Private Placements on October 6, 2022 and October 14, 2022, were deposited in a trust account (the “Trust Account”) maintained by Continental Stock Transfer & Trust Company as a trustee and will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”), and that invest only in direct U.S. government treasury obligations. These funds will not be released until the earlier of the completion of the initial Business Combination or the liquidation due to the Company’s failure to complete a Business Combination within the applicable period of time. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders. In addition, interest income earned on the funds in the Trust Account may be released to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred by the Company may be paid prior to a business combination only from the net proceeds of the IPO and private placement not held in the Trust Account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will provide its holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.15 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income tax obligations).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor and any of the Company’s officers or directors that may hold Insider Shares (as defined in Note 5) (the “Initial Stockholders”) and Chardan have agreed (a) to vote their Insider Shares, Private Shares (as defined in Note 4) and any Public Shares purchased during or after the IPO in favor of approving a Business Combination and (b) not to convert any shares (including the Insider Shares) in connection with a stockholder vote to approve, or sell the shares to the Company in any tender offer in connection with, a proposed Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Initial Stockholders and Chardan have agreed (a) to waive their redemption rights with respect to the Insider Shares, Private Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Initially, the Company had until 9 months from the closing of the IPO to consummate a Business Combination. In addition, if the Company anticipates that it may not be able to consummate initial business combination within 9 months, the Company’s insiders or their affiliates may, but are not obligated to, extend the period of time to consummate a business combination two times by an additional three months each time (for a total of 12 or 15 months to complete a business combination) (the “Combination Period”). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $750,000 ($0.15 per Public Share or an aggregate of $1,500,000) on or prior to the date of the applicable deadline.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2023, the Company held a special meeting of stockholders, at which the Company’s stockholders approved (i) an amendment to the Company’s amended and restated certificate of incorporation (the “Extension Amendment”) and (ii) an amendment (the “Trust Amendment”) to the Investment Management Trust Agreement, dated October 3, 2022, by and between the Company and Continental Stock Transfer & Trust Company to allow the Company to extend the Business Combination Period for a period of three months from July 6, 2023 to October 6, 2023, plus an option for the Company to further extend such date to January 6, 2024, and then on a monthly basis up to four times from January 6, 2024 to May 6, 2024. In connection with the stockholders’ vote at the special meeting, an aggregate of 2,487,090 shares with redemption value of approximately $25,943,773 (or $10.43 per share) of the Company’s common stock were tendered for redemption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 29, 2023, October 4, 2023 and December 29, 2023, Bestpath deposited in the Trust Account $210,000, $210,000 and $70,000 (totaling $490,000), respectively, and from January 2024 to May 2024, Bestpath provided loans of $70,000 each month to the Company to fund the amount required to extend the Business Combination Period to May 6, 2024. On May 2, 2024, Bestpath provided a loan of $20,000 to the Company to fund the amount required to extend the Business Combination Period to June 6, 2024. The Company issued an unsecured promissory note of $70,000 each time from January 2024 to May 2024 and $20,000 on May 2, 2024 to Bestpath in exchange for Bestpath depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 30, 2024, the Company held an annual stockholder meeting, at which the Company’s stockholders approved (i) an amendment to the Company’s amended and restated certificate of incorporation and (ii) an amendment to the Investment Management Trust Agreement, dated October 3, 2022 and amended on June 28, 2023, by and between the Company and Continental Stock Transfer & Trust Company to allow the Company to extend the Business Combination Period for up to twelve months on a monthly basis from May 6, 2024 to May 6, 2025. In connection with the stockholders’ vote at the annual meeting, an aggregate of 2,124,738 shares with redemption value of approximately $23.5 million (or $11.04 per share) of the Company’s common stock were tendered for redemption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of taxes payable, and less up to $50,000 of interest to pay dissolution expenses) divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor and Chardan have agreed to waive their liquidation rights with respect to the Insider Shares and Private Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor or Chardan acquires Public Shares in or after the IPO, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 7) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than $10.15.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.15 per Public Share, except as to any claims by a third party who executed a valid and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 23, 2023, the Company entered into an Agreement and Plan of Merger (the “Agreement”) with (i) Bestpath IoT Technology Ltd., a Cayman Islands exempted company (“Holdco”), (ii) Bestpath Group Limited, an exempted company incorporated in Cayman Islands and a direct wholly-owned subsidiary of Holdco (“PubCo”), (iii) Bestpath Merger Sub I Limited, an exempted company incorporated in Cayman Islands and a direct wholly-owned subsidiary of PubCo (“Merger Sub 1”), (iv) Bestpath Merger Sub II Inc., a Delaware corporation and a direct wholly-owned subsidiary of PubCo (“Merger Sub 2” and, together with PubCo and Merger Sub 1, each an “Acquisition Entity” and collectively, the “Acquisition Entities”), and (v) Bestpath (Shanghai) IoT Technology Co., Ltd., a PRC limited liability company (“Bestpath”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement, (i) Merger Sub 1 will merger with and into the Holdco (the “Initial Merger”) whereby the separate existence of Merger Sub 1 will cease and Holdco will be the surviving corporation of the Initial Merger and become a wholly owned subsidiary of PubCo, and (ii) following confirmation of the effective filing of the Initial Merger, Merger Sub 2 will merge with and into us (the “SPAC Merger”, and together with the Initial Merger, the “Mergers”), the separate existence of Merger Sub 2 will cease and will be the surviving corporation of the SPAC Merger and a direct wholly owned subsidiary of PubCo.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Mergers implies a current equity value of Bestpath at $1.2 billion prior to the closing of the Mergers (the “Closing”). As a result of the Mergers, among other things, (i) each outstanding share in Holdco shall automatically be cancelled, and in exchange for the right to receive newly issued ordinary shares in PubCo (“PubCo Ordinary Shares”) at the Holdco Exchange Ratio; (ii) each outstanding SPAC Unit will be automatically detached; (iii) each unredeemed outstanding share of common stock will be cancelled in exchange for the right to receive one PubCo Ordinary Share, (iv) every five (5) outstanding our rights will be cancelled and cease to exist in exchange for one PubCo Ordinary Share, and (v) each SPAC UPO will automatically be cancelled and cease to exist in exchange for one (1) PubCo UPO. Each outstanding PubCo Ordinary Share will have a value at the time of the Closing of $10.00.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern Consideration</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, the Company had $339 in cash and working capital deficit of $1,914,142. The Company’s liquidity needs prior to the consummation of the IPO had been satisfied through a payment from the Sponsor of $25,000 for the Insider Shares and the loan under an unsecured promissory note from the Sponsor of $300,000. On February 8, 2023, February 23, 2023, March 31, 2023, and June 26, 2023, the Sponsor provided a loan of $100,000, $140,000, $130,000, and $79,780 (excluding $99,846 converted from amount due to related party), respectively, to be used, in part, for transaction costs related to the Business Combination (see Note 5). On June 29, 2023, October 4, 2023 and December 29, 2023, Bestpath deposited into the Trust Account $210,000, $210,000 and $70,000 (totaling $490,000), respectively, and from January 2024 to April 2024, Bestpath provided loans of $70,000 each month to the Company to fund the amount required to extend the Business Combination Period to May 6, 2024. On May 2, 2024, Bestpath provided a loan of $20,000 to the Company to fund the amount required to extend the Business Combination Period to June 6, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has until June 6, 2024 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution. The Company expects to continue to incur significant professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet its obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined that if the Company is unable to complete a Business Combination by June 6, 2024 (unless the Company extends the time to complete a Business Combination), then the Company will cease all operations except for the purpose of liquidating. The date for liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated the impact of persistent inflation and rising interest rates, financial market instability, including the recent bank failures, the lingering effects of the COVID-19 pandemic and certain geopolitical events, including the conflict in Ukraine and the surrounding region, and has concluded that while it is reasonably possible that the risks and uncertainties related to or resulting from these events could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of these risks and uncertainties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, it has been determined that the IR Act tax provisions have an impact to the Company’s fiscal 2023 tax provision as there were redemptions by the public stockholders in June 2023; as a result, the Company recorded $259,438 excise tax liability as of December 31, 2023. The Company will continue to monitor for updates to the Company’s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company’s tax provision in future periods.</p>
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2021-03-11
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2023	aqu	Underwriters Option Period From Date Of Initial Public Offering UnderwritersOptionPeriodFromDateOfInitialPublicOffering	P45Y
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2023	aqu	Investments Maximum Maturity Term InvestmentsMaximumMaturityTerm	P185D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5000001	usd
CY2023	aqu	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2023	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	2487090	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25943773	usd
CY2023Q2	us-gaap	Other Notes Payable OtherNotesPayable	70000	usd
CY2023Q4	aqu	Maximum Net Interest To Pay Dissolution Expenses MaximumNetInterestToPayDissolutionExpenses	50000	usd
CY2023	aqu	Trust Account Per Share TrustAccountPerShare	10.15
CY2023Q4	us-gaap	Equity Fair Value Disclosure EquityFairValueDisclosure	1200000000	usd
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2023Q4	us-gaap	Cash Cash	339	usd
CY2023Q4	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	1914142	usd
CY2023	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	25000	usd
CY2023Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	300000	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	100000	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	140000	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	130000	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	79780	usd
CY2022Q3	us-gaap	Derivative Average Forward Interest Rate DerivativeAverageForwardInterestRate	0.01	pure
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.01	pure
CY2023	us-gaap	Excise And Sales Taxes ExciseAndSalesTaxes	259438	usd
CY2023	us-gaap	Reclassifications Reclassifications	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 — Revision of Prior Period Financial Information</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the preparation of this Annual Report on Form 10-K, the Company determined that it had not appropriately classified two balance sheet accounts, Investments Held in Trust Account and Deferred Underwriting Commissions, under accounting principles generally accepted in the United States of America (“U.S. GAAP”). Investments Held in Trust Account and Deferred Underwriting Commissions accounts were misclassified as current assets and current liabilities, respectively, on the balance sheets, resulting in misstatements of current and non-current assets accounts and current and non-current liabilities accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Staff Accounting Bulletin (“SAB”) 99, “Materiality”, and SAB 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements”, the Company evaluated the materiality of the errors from qualitative and quantitative perspectives, individually and in aggregate, and concluded that the errors were material to the Balance Sheet as of October 6, 2022 (IPO date), for the fiscal year ended December 31, 2022, and the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023. Management revised the impacted Balance Sheets for the fiscal year ended December 31, 2022, and the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023. Refer to Note 12 for revised annual and quarterly financial statements.</p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing of financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2023Q4	us-gaap	Cash Cash	339	usd
CY2022Q4	us-gaap	Cash Cash	57284	usd
CY2023Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	31960267	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	55421229	usd
CY2023Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	2121986	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	436852	usd
CY2023	us-gaap	Deferred Policy Acquisition Costs Text Block1 DeferredPolicyAcquisitionCostsTextBlock1	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Offering Costs</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirements of Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (the “ASC”) Topic 340-10-S99-1, “Other Assets and Deferred Costs – SEC Materials” and SEC Staff Accounting Bulletin Topic 5A, “Expenses of Offering”. Offering costs are allocated between public shares and public rights based on the estimated fair values of public shares and public rights at the date of issuance. Deferred offering costs consisted principally of underwriting, legal, accounting and other expenses were charged to stockholders’ equity upon the completion of the IPO on October 6, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	997917	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	164068	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	10332578	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3560360	usd
CY2023	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-9334661	usd
CY2022	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-3396292	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of December 31, 2023 and December 31, 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2023	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023	aqu	Common Stock Subject To Possible Redemption CommonStockSubjectToPossibleRedemption	10332578	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	54171800	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6446444	usd
CY2022	aqu	Allocation Of Offering Costs Related To Redeemable Shares AllocationOfOfferingCostsRelatedToRedeemableShares	-3714253	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3560360	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	47571463	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	10332578	usd
CY2023	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	25943773	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	31960268	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	12515.4	shares
CY2021Q2	aqu	Common Stock Aggregated Consideration Value commonStockAggregatedConsiderationValue	25000	usd
CY2021Q2	aqu	Share Issued And Outstanding Percentage ShareIssuedAndOutstandingPercentage	0.20	pure
CY2023	aqu	Subject To Certain Limited Exceptions Percentage SubjectToCertainLimitedExceptionsPercentage	0.50	pure
CY2022Q4	us-gaap	Repayments Of Debt RepaymentsOfDebt	200000	usd
CY2022Q4	us-gaap	Repayments Of Debt RepaymentsOfDebt	100000	usd
CY2023Q2	us-gaap	Capital Units CapitalUnits	99846	usd
CY2023Q2	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	99846	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	97052	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	99846	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	97052	usd
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	210000	usd
CY2023Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	70000	usd
CY2023	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	490000	usd
CY2022	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	0	usd
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	750000	shares
CY2023	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	812577	usd
CY2023	aqu	Payments To Acquire Businesses From Amounts Held In Trust Account PaymentsToAcquireBusinessesFromAmountsHeldInTrustAccount	1896013	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	97509	shares
CY2022Q4	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	1.15	pure
CY2023Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	31960267	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	55421229	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	174157	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	33997	usd
CY2023Q4	aqu	Amortization Of Startup Cost AmortizationOfStartupCost	2897	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	29727	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	37144	usd
CY2023Q4	aqu	Deferred Taxs Asset Gross DeferredTaxsAssetGross	141533	usd
CY2022Q4	aqu	Deferred Taxs Asset Gross DeferredTaxsAssetGross	-3147	usd
CY2023Q4	aqu	Deferred Tax Asset Valuation Allowances DeferredTaxAssetValuationAllowances	-3147	usd
CY2022Q4	aqu	Deferred Tax Asset Valuation Allowances DeferredTaxAssetValuationAllowances	-3147	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	144680	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	406920	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	51753	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-144680	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4071	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4071	usd
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	262240	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	51753	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2023	aqu	Effective Income Tax Rate Reconciliation Change In Deferred Tax Transaction Costs Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxTransactionCostsAllowance	0.035	pure
CY2022	aqu	Effective Income Tax Rate Reconciliation Change In Deferred Tax Transaction Costs Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxTransactionCostsAllowance	0.049	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.037	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.019	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	0.208	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	0.24	pure
CY2023Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	0	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	4071	usd
CY2023	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations	262240	usd
CY2022	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations	51753	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent		usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes		usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022	aqu	Cash Withdrawn From Trust Account To Public Stockholder Redemption CashWithdrawnFromTrustAccountToPublicStockholderRedemption		usd
CY2022	aqu	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount		usd
CY2022	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023	aqu	Payment Of Underwriters Commissions PaymentOfUnderwritersCommissions		usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	aqu	Initial Classification Of Common Stock Subject To Redemption InitialClassificationOfCommonStockSubjectToRedemption		usd
CY2023	aqu	Allocation Of Offering Costs To Common Stock Subject To Redemption AllocationOfOfferingCostsToCommonStockSubjectToRedemption		usd
CY2023	aqu	Deferred Offering Costs In Accrued Offering Expenses DeferredOfferingCostsInAccruedOfferingExpenses		usd
CY2022	aqu	Exercise Tax Payable Charged Against Retained Earnings ExerciseTaxPayableChargedAgainstRetainedEarnings		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	aqu	Other Payable Due To Related Party OtherPayableDueToRelatedParty		usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards		usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards		usd
CY2022Q4	aqu	Amortization Of Startup Cost AmortizationOfStartupCost		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001861063

Files In Submission

Name	View Source	Status
0001213900-24-039767-index-headers.html	Edgar Link	pending
0001213900-24-039767-index.html	Edgar Link	pending
0001213900-24-039767.txt	Edgar Link	pending
0001213900-24-039767-xbrl.zip	Edgar Link	pending
aqu-20231231.xsd	Edgar Link	pending
ea0203898-10k_aquaron.htm	Edgar Link	pending
ea020389801ex10-11_aquaron.htm	Edgar Link	pending
ea020389801ex10-12_aquaron.htm	Edgar Link	pending
ea020389801ex31-1_aquaron.htm	Edgar Link	pending
ea020389801ex31-2_aquaron.htm	Edgar Link	pending
ea020389801ex32-1_aquaron.htm	Edgar Link	pending
ea020389801ex32-2_aquaron.htm	Edgar Link	pending
ea020389801ex97-1_aquaron.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
ea0203898-10k_aquaron_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aqu-20231231_def.xml	Edgar Link	unprocessable
aqu-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aqu-20231231_cal.xml	Edgar Link	unprocessable
aqu-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQU
Aquaron Acquisition Corp. Stock $aqu

2024 Q1 Form 10-K Financial Statement

#000121390024039767 Filed on May 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQU Aquaron Acquisition Corp. Stock $aqu

2024 Q1 Form 10-K Financial Statement

#000121390024039767 Filed on May 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQU
Aquaron Acquisition Corp. Stock $aqu